
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
Details : RYZ401 is a Radiolabeled Compound drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Gastro-enteropancreatic neuroendocrine tumor.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
September 10, 2025

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 225-Ac Dotatate RYZ101
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
RYZ101 for the Treatment of Progressive or Recurrent Intracranial Meningioma
Details : 225-Ac Dotatate RYZ101 is a Radiolabeled Compound drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Meningioma.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
September 02, 2025
Lead Product(s) : 225-Ac Dotatate RYZ101
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Philochem AG Announces the Licensing of Worldwide Rights to OncoACP3 to RayzeBio
Details : Under the licensing agreement, RayzeBio will hold the rights to develop, manufacture, and commercialise 68-Ga OncoACP3, a clinical stage therapeutic and diagnostic agent targeting prostate cancer.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : $350.0 million
June 10, 2025

Details : RYZ801 is a Peptide drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
December 10, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : RYZ101
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RYZ101 is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Breast Neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
September 19, 2024
Lead Product(s) : RYZ101
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Details : 225-Ac Dotatate is a Radiolabeled Compounds drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Multiple Myeloma.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
May 13, 2024

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 225-Ac Dotatate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : $4.1 million
Deal Type : Acquisition
Bristol Myers Squibb Acquires RayzeBio, Adding Actinium-Based Radiopharmaceuticals
Details : Bristol acquires RYZ101 (actinium-225 dotatate), targeting somatostatin receptor 2, currently evaluated for SSTR-positive gastroenteropancreatic neuroendocrine tumors.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : $4.1 million
February 26, 2024
Lead Product(s) : 225-Ac Dotatate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : $4.1 million
Deal Type : Acquisition

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 225-Ac Dotatate
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : $4,100.0 million
Deal Type : Acquisition
Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
Details : By acquiring RayzeBio’s differentiated actinium-based radiopharmaceutical platform, BMS will establish its presence in one of the most promising and fastest-growing new modalities for solid tumors, by delivering radioactive payloads to cancer cells in ...
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : $4,100.0 million
December 26, 2023
Lead Product(s) : 225-Ac Dotatate
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Bristol Myers Squibb
Deal Size : $4,100.0 million
Deal Type : Acquisition

Details : RYZ101 (Actinium-225 DOTATATE) is an investigational targeted radiopharmaceutical therapy, designed to deliver a highly potent radioisotope, Actinium-225 (Ac225), in patients with SSTR+ gastroenteropancreatic neuroendocrine tumors.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
October 24, 2023

Details : The proceeds will advance clinical development of RYZ101 (actinium-225 dotatate) in company's Phase 3 trial in GEP-NETs, RYZ101 through Phase 1b efficacy data in ES-SCLC and IND enabling activities and clinical development of RYZ801 and RYZ811 in HCC thr...
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Undisclosed
September 19, 2023
